---
figid: PMC5384128__13045_2017_455_Fig1_HTML
figlink: /pmc/articles/PMC5384128/figure/Fig1/
number: F1
caption: 'Adaptive resistance and innate resistance. (Left, adaptive resistance) Upon
  recognition of tumor antigens, TILs produce IFN-γ, which induces PD-L1 expression
  via nuclear NF-κB activation and the PKD2 signal pathway. In tumor hypoxia microenvironmental
  condition, HIF-1 regulates the expression of PD-L1 by binding directly to the hypoxia
  response element-4 in the PD-L1 proximal promoter. Upon binding to PD-1, PD-L1 delivers
  a suppressive signal to T cells, leading to T cell dysfunction. (Right, innate resistance)
  Tumor cell PD-L1 expression that might be related to oncogenic signaling pathways
  or oncogenic gene mutation as inherent in the tumor cell. Oncogenic signals (such
  as PI3K/Akt/mTOR, JAK/STAT 3, and EGFR/MAPK pathway) or oncogenic gene mutation
  (such as PTEN, ALK, and EGFR) upregulate PD-L1 expression on tumors as innate resistance.
  Abbreviations: IFN-γ interferon-γ, TILs tumor-infiltrating lymphocytes, NF-κB nuclear
  factor-kappaB, PI3K phosphatidylinositol 3-kinase, HIF-1 hypoxia inducible factor-1,
  JAK/STAT3 Janus kinase/signal transducer and activator of transcription 3, EGFR/MAPK
  epidermal growth factor receptor/mitogen-activated protein kinase, ALK anaplastic
  lymphoma kinase, PKD2 polycystin 2, PD-1 programmed death 1, PD-L1 programmed cell
  death-ligand 1, AKT protein kinase B, mTOR mammalian target of rapamycin, PTEN phosphatase
  and tensin homolog'
pmcid: PMC5384128
papertitle: 'Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment
  strategy.'
reftext: Song Xue, et al. J Hematol Oncol. 2017;10:81.
pmc_ranked_result_index: '48307'
pathway_score: 0.8343102
filename: 13045_2017_455_Fig1_HTML.jpg
figtitle: Adaptive resistance and innate resistance
year: '2017'
organisms:
- Homo sapiens
ndex: 87fe8e03-df22-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5384128__13045_2017_455_Fig1_HTML.html
  '@type': Dataset
  description: 'Adaptive resistance and innate resistance. (Left, adaptive resistance)
    Upon recognition of tumor antigens, TILs produce IFN-γ, which induces PD-L1 expression
    via nuclear NF-κB activation and the PKD2 signal pathway. In tumor hypoxia microenvironmental
    condition, HIF-1 regulates the expression of PD-L1 by binding directly to the
    hypoxia response element-4 in the PD-L1 proximal promoter. Upon binding to PD-1,
    PD-L1 delivers a suppressive signal to T cells, leading to T cell dysfunction.
    (Right, innate resistance) Tumor cell PD-L1 expression that might be related to
    oncogenic signaling pathways or oncogenic gene mutation as inherent in the tumor
    cell. Oncogenic signals (such as PI3K/Akt/mTOR, JAK/STAT 3, and EGFR/MAPK pathway)
    or oncogenic gene mutation (such as PTEN, ALK, and EGFR) upregulate PD-L1 expression
    on tumors as innate resistance. Abbreviations: IFN-γ interferon-γ, TILs tumor-infiltrating
    lymphocytes, NF-κB nuclear factor-kappaB, PI3K phosphatidylinositol 3-kinase,
    HIF-1 hypoxia inducible factor-1, JAK/STAT3 Janus kinase/signal transducer and
    activator of transcription 3, EGFR/MAPK epidermal growth factor receptor/mitogen-activated
    protein kinase, ALK anaplastic lymphoma kinase, PKD2 polycystin 2, PD-1 programmed
    death 1, PD-L1 programmed cell death-ligand 1, AKT protein kinase B, mTOR mammalian
    target of rapamycin, PTEN phosphatase and tensin homolog'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK14
  - MAPK11
  - MAPK9
  - TYK2
  - MAPK3
  - MAPK12
  - MAPK8
  - MAPK1
  - PDCD1
  - JAK3
  - STAT3
  - NFKB1
  - AKT2
  - SETD2
  - MAPK13
  - AKT3
  - PKD2
  - EGFR
  - MAPK10
  - PTEN
  - ALK
  - AKT1
  - JAK2
  - MTOR
  - JAK1
  - Cancer
genes:
- word: EGFR/MAPK,
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: EGFR/MAPK,
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: EGFR/MAPK,
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: JAK/STAT3,EGFR/MAPK,
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: EGFR/MAPK,
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: EGFR/MAPK,
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: EGFR/MAPK,
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: EGFR/MAPK,
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: JAK/STAT3,EGFR/MAPK,
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK/STAT3,EGFR/MAPK,
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: (PI3K/AKT/MTOR.
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: HIF-1
  symbol: HIF-1
  source: hgnc_alias_symbol
  hgnc_symbol: SETD2
  entrez: '29072'
- word: EGFR/MAPK,
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: (PI3K/AKT/MTOR.
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PKD2
  symbol: PKD2
  source: hgnc_symbol
  hgnc_symbol: PKD2
  entrez: '5311'
- word: EGFR/MAPK,
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: EGFR/MAPK,
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: PTEN,ALK,EGFR)
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: ALK,
  symbol: ALK
  source: hgnc_symbol
  hgnc_symbol: ALK
  entrez: '238'
- word: (PI3K/AKT/MTOR.
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: JAK/STAT3,EGFR/MAPK,
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: (PI3K/AKT/MTOR.
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: JAK/STAT3,EGFR/MAPK,
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC5384128__F1
redirect_from: /figures/PMC5384128__F1
figtype: Figure
---
